New hope for tough esophageal cancer: triple therapy shows promise
NCT ID NCT07272291
First seen Jan 04, 2026 · Last updated May 01, 2026 · Updated 19 times
Summary
This study tests a new treatment for people with esophageal cancer that didn't shrink after standard therapy. Participants will get low-dose radiation, chemotherapy, and an immunotherapy drug called toripalimab before surgery. The goal is to see if adding radiation helps more tumors shrink or disappear. After surgery, some patients may continue toripalimab for up to a year to keep the cancer from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.